Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Swedish Orphan Biovitrum AB (SOBIN) Stock Price & Analysis

SOBIN Stock Chart & Stats

$903.50$0.00(0.00%)
At close:
No data to display
Day’s Range
$903.50 - $903.50
52-Week Range
$525.34 - $905.00
Previous Close
$903.50
Volume
N/A
Average Volume (3M)
64
Market Cap
MXN 323.71B
Enterprise Value
MXN 169.97B
Total Cash (Recent Filing)
MXN 1.00B
Total Debt (Recent Filing)
MXN 16.15B
Price to Earnings (P/E)
25.6
Beta
-0.07
Next Earnings
Feb 04, 2027 (Est.)
EPS Estimate
12.74
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue Growth

Consistent revenue expansion, followed by sharper growth in 2026 TTM, indicates rising demand for Sobi’s rare-disease portfolio and improving commercial execution. If sustained, this larger revenue base can support continued investment in therapies, indications, and geographic reach over the next several quarters.

Strong Cash Generation

Positive operating cash flow across every period and strong 2026 TTM free cash flow show that the business can convert operations into internal funding. High free-cash-flow conversion in 2025 and 2026 TTM strengthens capacity to support development, commercialization, and other strategic priorities.

Manageable Leverage

Debt below equity across all periods and growing equity provide a meaningful financial buffer for a specialty biopharma business. Moderate leverage should preserve flexibility to invest in its rare-disease portfolio and absorb operational variation, provided debt growth remains controlled.

Bears Say

Lower Net Profitability

Despite strong gross profit, EBITDA, and improved operating profitability, lower net profitability in 2026 TTM suggests that earnings below the operating line remain a drag. This weakens the conversion of commercial progress into bottom-line returns and may constrain durable earnings visibility.

Historical Cash-Flow Volatility

Strong recent free cash flow is encouraging, but negative free cash flow in 2023 and large historical swings indicate that cash generation has not been consistently predictable. Such variability can complicate long-term planning and reduce confidence in the durability of reported earnings.

Rising Debt Reduces Flexibility

Although leverage remains moderate, higher total debt versus 2025 increases financial commitments and reduces room to respond if profitability weakens. The added borrowing could limit capital-allocation flexibility, particularly while net profitability remains below earlier-period levels.

Swedish Orphan Biovitrum AB News

SOBIN FAQ

What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest stock price was $525.34 and its highest was $905.00 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Swedish Orphan Biovitrum AB’s market cap is Mex$323.71B.
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s next earnings report is estimated for Feb 04, 2027 (not yet confirmed), which is in 94 days.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Oct 27, 2026. The company reported $12.856 earnings per share for the quarter, beating the consensus estimate of $11.559 by $1.297.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is 12.74.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 357,636,500 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of $12.856 in its last earnings report, beating expectations of $11.559. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in MX:SOBIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology